For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Additional Safety Measures for Xocova “Not Needed at This Time”: MHLW Panel
March 24, 2023
- MHLW Orders Label Revisions for TB Drugs, Steboronine
March 24, 2023
- Japan to Designate 3 More Diseases as Intractable Illnesses
March 24, 2023
- MHLW Panel Begins Discussions on Revision of Basic Policy for Blood Products
March 23, 2023
- Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
- Chuikyo’s SaMD Working Group to Compile Opinion by July
March 23, 2023
- Majority of Pharmacists Think Setting Up Integrated Drug Supply Website Is Vital: MHLW Study
March 22, 2023
- Japan to Tap Patient-Initiated Mixed Care Scheme for Pediatric Cancer Meds
March 22, 2023
- MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
- MHLW Panel OKs 184 More Health Damage Claims for COVID-19 Jabs
March 22, 2023
- Japan Approves J-TEC’s Cell Sheet for Vitiligo, Aurion’s Bullous Keratopathy Therapy
March 22, 2023
- Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
- Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
March 20, 2023
- Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
March 20, 2023
- Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
- 97 Health Damages Reported for Kymriah in Japan: April-September
March 17, 2023
- Japan to Add Purchased Doses of Paxlovid, Xocova to Govt Stockpile
March 17, 2023
- Health Minister Vows to Make Use of Govt-Purchased Xocova
March 17, 2023
- Japan Damage Relief Panel Recognizes 11 More Deaths Possibly Tied to COVID Jabs
March 16, 2023
- PMDA Sets Target Duration of SaMD Priority Reviews to 6 Months in FY2024 Plan
March 14, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…